Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.55 |
| ▸ | CD14 | P08571 | 6/20 | 0.55 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PTPRB | P23467 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13987040 | 0.78 | ELANE (0.58) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL16545619 | 0.76 | TLR4 (0.56) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL8955766 | 0.76 | CD69 (0.52) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL11415045 | 0.74 | CASP1 (0.35) | — | |
| SCHEMBL14617492 | 0.74 | TLR4 (0.57) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL14617493 | 0.73 | ELANE (0.53) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL16501729 | 0.73 | ATM (0.36) | TLR4CD14LY96KCNA3KCNA5 | |
| SCHEMBL9504541 | 0.72 | PDE3B (0.36) | TLR4CD14LY96 | |
| SCHEMBL14617494 | 0.72 | PTPRC (0.57) | TLR4CD14LY96ELANECD69 | |
| SCHEMBL9504435 | 0.71 | LTB4R (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642656-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
| US-8207228-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2011157961-A3 | METHOD OF AUTOMATIC IDENTIFICATION OF THE CONTOURS OF A PREDEFINED BONE, DERIVED METHODS AND CORRESPONDING COMPUTER PROGRAM PRODUCTS | IMASCAP (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2404895-A1 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | Regents of the University of Minnesota (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-1802291-B1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | UNIV MINNESOTA (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | TLR4 3671/4885CD14 2702/4885LY96 1170/4885 |
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | TLR4 3671/4885CD14 2702/4885LY96 1170/4885 |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | TLR4 3671/4885CD14 2702/4885LY96 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.